XML 20 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Cumulative Effect, Period of Adoption, Adjustment
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Loss
Beginning Balance (in shares) at Dec. 31, 2020     34,481          
Beginning Balance at Dec. 31, 2020 $ 1,400,181   $ 345 $ 0   $ 1,506,271   $ (106,435)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 234,966         234,966    
Comprehensive (Loss) Income                
Cumulative translation adjustment (22,405)             (22,405)
Issuance of common stock in connection with:                
Exercise of options (in shares)     78          
Exercise of options 2,694   $ 1 2,693        
Restricted share grants (in shares)     196          
Restricted share grants (11,635)   $ 1 (11,636)        
Stock units issued under incentive compensation plan 2,603     2,603        
Purchase and retirement of common stock (in shares)     (422)          
Purchase and retirement of common stock (46,132)   $ (4) (3,047)   (43,081)    
Conversion of convertible senior notes due 2023 (2)     (2)        
Share-based compensation 23,051     23,051        
Ending Balance (in shares) at Dec. 31, 2021     34,333          
Ending Balance at Dec. 31, 2021 1,583,321 $ (12,053) $ 343 13,662 $ (34,131) 1,698,156 $ 22,078 (128,840)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 235,514         235,514    
Comprehensive (Loss) Income                
Cumulative translation adjustment (47,882)             (47,882)
Issuance of common stock in connection with:                
Exercise of options (in shares)     68          
Exercise of options 2,317     2,317        
Restricted share grants (in shares)     199          
Restricted share grants (17,953)   $ 2 (17,955)        
Stock units issued under incentive compensation plan 1,664     1,664        
Purchase and retirement of common stock (in shares)     (574)          
Purchase and retirement of common stock (88,606)   $ (5) (88,601)        
Conversion of convertible senior notes due 2023 (15)     (15)        
Share-based compensation 25,414     25,414        
Reclassification of negative additional paid-in capital $ 0     97,645   (97,645)    
Ending Balance (in shares) at Dec. 31, 2022 34,026   34,026          
Ending Balance at Dec. 31, 2022 $ 1,681,721   $ 340 0   1,858,103   (176,722)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 274,892         274,892    
Comprehensive (Loss) Income                
Cumulative translation adjustment $ 26,262             26,262
Issuance of common stock in connection with:                
Exercise of options (in shares) 38   38          
Exercise of options $ 1,297     1,297        
Restricted share grants (in shares)     108          
Restricted share grants (16,374)   $ 1 (16,375)        
Stock units issued under incentive compensation plan 2,274     2,274        
Settlement of conversion premium of convertible senior notes due 2023 (in shares)     1,461          
Settlement of conversion premium of convertible senior notes due 2023 (6)   $ 15 (21)        
Purchase and retirement of common stock (in shares)     (112)          
Purchase and retirement of common stock (17,799)   $ (1) (17,798)        
Conversion of convertible senior notes due 2023 (381)     (381)        
Share-based compensation 29,534     29,534        
Reclassification of negative additional paid-in capital $ 0     18,230   (18,230)    
Ending Balance (in shares) at Dec. 31, 2023 35,521   35,521          
Ending Balance at Dec. 31, 2023 $ 1,981,420   $ 355 $ 16,760   $ 2,114,765   $ (150,460)